Form 4: Lilly Endowment Inc. Sells Shares in Eli Lilly & Co.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings on July 1, 2024.

Summary

• Lilly Endowment Inc. sold 53,949 shares of Eli Lilly & Co. common stock at a weighted average price of $915.171 per share on July 1, 2024.
• Additionally, Lilly Endowment Inc. sold 4,800 shares of Eli Lilly & Co. common stock at a weighted average price of $916.295 per share on the same day.
• Following these transactions, Lilly Endowment Inc. beneficially owns 97,308,620 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing a stock sale by a major shareholder. It is neutral in sentiment as it simply reports a transaction.

Management Comments

• Ben W. Blanton, Vice President, Secretary & General Counsel, signed the form on behalf of Lilly Endowment Inc.

Industry Context

This is a routine filing related to a significant shareholder's transactions in the company's stock. Such filings are common and provide transparency into insider trading activity.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders in publicly traded companies.
• The transactions are within the normal range of trading activity for a large institutional investor like Lilly Endowment Inc.
• Comparable filings can be seen from other large shareholders of publicly traded companies.

Stakeholder Impact

• The sale of shares by a major shareholder could have a minor impact on the stock price, but is unlikely to be significant given the size of the company and the relatively small number of shares sold.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, beneficial ownership, LLY